Amgen (NASDAQ:AMGN) Raised to “Buy” at Wall Street Zen

Amgen (NASDAQ:AMGN) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.

Several other analysts also recently weighed in on AMGN. Leerink Partners reiterated a “market perform” rating and set a $355.00 price target on shares of Amgen in a research note on Thursday, March 5th. Cantor Fitzgerald reiterated a “neutral” rating and set a $350.00 price target on shares of Amgen in a research note on Wednesday, April 8th. Jefferies Financial Group started coverage on Amgen in a research note on Tuesday, March 10th. They set a “hold” rating and a $350.00 price target on the stock. Truist Financial boosted their price target on Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a research note on Thursday, January 8th. Finally, Freedom Capital downgraded Amgen from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $355.84.

Amgen Trading Down 0.0%

Shares of NASDAQ:AMGN opened at $350.92 on Friday. Amgen has a 12-month low of $261.43 and a 12-month high of $391.29. The business’s fifty day simple moving average is $363.87 and its 200-day simple moving average is $335.48. The company has a market capitalization of $189.39 billion, a PE ratio of 24.66, a P/E/G ratio of 3.30 and a beta of 0.47. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. During the same period in the previous year, the business earned $5.31 EPS. The firm’s revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities research analysts predict that Amgen will post 20.62 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Amgen

Large investors have recently bought and sold shares of the company. Old North State Trust LLC grew its position in Amgen by 21.6% in the fourth quarter. Old North State Trust LLC now owns 2,568 shares of the medical research company’s stock worth $841,000 after acquiring an additional 456 shares during the period. J. Derek Lewis & Associates Inc. purchased a new position in Amgen in the fourth quarter worth approximately $269,000. Purpose Unlimited Inc. purchased a new position in Amgen in the fourth quarter worth approximately $1,299,000. Cornerstone Planning LLC purchased a new position in Amgen in the fourth quarter worth approximately $2,155,000. Finally, Rockefeller Capital Management L.P. grew its position in Amgen by 27.5% in the fourth quarter. Rockefeller Capital Management L.P. now owns 642,161 shares of the medical research company’s stock worth $210,186,000 after acquiring an additional 138,577 shares during the period. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: China approval for tarlatamab expands Amgen’s lung-cancer market access and supports future revenue in a large oncology market — a meaningful commercial win for a new oncology asset. Amgen’s lung cancer drug tarlatamab wins China approval
• Positive Sentiment: Phase‑4 FORWARD II gout study update: a less‑frequent Krystexxa dosing schedule could improve patient adherence and lifetime drug value, which would be positive for product uptake and revenue stability. Amgen’s FORWARD II Gout Study
• Positive Sentiment: Analyst bullishness on fundamentals: Zacks argues Amgen is poised to beat earnings again, supported by its recent history of surprise results and solid guidance — this can underpin near‑term sentiment ahead of the next report. Why Amgen (AMGN) is Poised to Beat Earnings Estimates Again
• Positive Sentiment: Royal Bank of Canada raised its price target to $370, signaling upside from some institutional analysts and suggesting conviction in Amgen’s mid‑term growth drivers. Royal Bank Of Canada Increases Amgen Price Target
• Neutral Sentiment: Guggenheim nudged its target to $351 while retaining a neutral rating — little immediate directional impact given the price is near that level. Amgen Price Target Raised to $351 at Guggenheim
• Neutral Sentiment: Short‑interest data reported for April appears inconsistent/erroneous (reads as 0 shares / NaN increase), so it’s unlikely to be a reliable driver of today’s action. (data entry)
• Neutral Sentiment: Media pieces highlighting Amgen’s profitability and recent TEPEZZA subcutaneous Phase‑3 topline results reinforce the company’s longer‑term value story but are incremental to near‑term price moves. Is Amgen One of the Most Profitable Value Stocks?
• Negative Sentiment: Morgan Stanley’s latest stance (equal‑weight, target raised only to $326) and other hold ratings emphasize limited near‑term upside vs. current levels — that analyst positioning is weighing on the stock. Morgan Stanley equal weight on Amgen

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.